Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Kymera Therapeutics Inc KYMR

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

GlobeNewswire June 1, 2024

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

GlobeNewswire May 29, 2024

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

GlobeNewswire May 23, 2024

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

GlobeNewswire May 22, 2024

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

GlobeNewswire May 14, 2024

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

GlobeNewswire May 8, 2024

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire May 2, 2024

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

GlobeNewswire April 25, 2024

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

GlobeNewswire April 8, 2024

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

GlobeNewswire March 8, 2024

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire February 28, 2024

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

GlobeNewswire February 22, 2024

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

GlobeNewswire February 15, 2024

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

GlobeNewswire January 31, 2024

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

GlobeNewswire January 9, 2024

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire January 9, 2024

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

GlobeNewswire January 5, 2024

Kymera Therapeutics Announces Proposed Public Offering

GlobeNewswire January 4, 2024

R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

GlobeNewswire January 4, 2024

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

GlobeNewswire January 2, 2024